Last reviewed · How we verify
Diprolene (BETAMETHASONE DIPROPIONATE)
Diprolene works by binding to the glucocorticoid receptor in the skin, which reduces inflammation and suppresses the immune system.
Diprolene (BETAMETHASONE DIPROPIONATE) is a corticosteroid medication originally developed by SCHERING and currently owned by the same company. It targets the glucocorticoid receptor and is used to treat various skin conditions, including atopic dermatitis, contact dermatitis, and plaque psoriasis. Diprolene is a small molecule corticosteroid that has been FDA-approved since 1975 and is now available as a generic medication. It is off-patent and has multiple generic manufacturers. Key safety considerations include potential skin thinning and increased risk of infections.
At a glance
| Generic name | BETAMETHASONE DIPROPIONATE |
|---|---|
| Sponsor | Merck & Co. |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1975 |
Mechanism of action
Mechanism of Action. Clotrimazole is an imidazole antifungal agent. Imidazoles inhibit 14--demethylation of lanosterol in fungi by binding to one of the cytochrome P-450 enzymes. This leads to the accumulation of 14--methylsterols and reduced concentrations of ergosterol, sterol essential for normal fungal cytoplasmic membrane. The methylsterols may affect the electron transport system, thereby inhibiting growth of fungi.
Approved indications
- Atopic dermatitis
- Contact dermatitis
- Discoid lupus erythematosus
- Eruption of skin
- Granuloma annulare
- Lichen simplex chronicus
- Plaque psoriasis
- Primary cutaneous T-cell lymphoma
- Pruritus ani
- Pruritus of genital organs
- Scalp psoriasis
- Seborrheic dermatitis
- Tinea corporis
- Tinea cruris
- Tinea pedis
Common side effects
- Skin atrophy
- Non-facial atrophy
Key clinical trials
- Assessing Psoriasis Treatment Outcomes (NA)
- A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects (PHASE3)
- Comparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty (NA)
- Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS) (PHASE4)
- Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) (PHASE2,PHASE3)
- Comparison of Efficacy of Betamethasone Gel With Lidocaine Gel in Prevention of Post Endotracheal Intubation Sore Throat. (PHASE1,PHASE2)
- EFFECT OF INTRAARTICULAR TRIAMCINOLONE HEXACETONIDE AND BETAMETHASONE ON INTRAOCULAR PRESSURE (PHASE4)
- Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study (PHASE4)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 9775851 | 2030-08-31 | Formulation |
| 9364485 | 2030-08-31 | Formulation |
| 9655907 | 2030-08-31 | Formulation |
| 10179137 | 2030-08-31 | Formulation |
| 9433630 | 2030-08-31 | Formulation |
| 9877974 | 2030-08-31 | Formulation |
| 9439911 | 2030-08-31 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diprolene CI brief — competitive landscape report
- Diprolene updates RSS · CI watch RSS
- Merck & Co. portfolio CI